You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

Symptom assessment for your COPD patients

Go to Close Top

COPD Assessment Test™ (CAT) 1

You can help your patients find out how their COPD is affecting their lives and how well they are managing their symptoms by simply using the COPD Assessment Test (CAT). – CAT is a questionnaire designed for use in routine clinical practice to measure the impact of COPD on patients’ lives and how this changes over time. 1

  • The CAT is suitable for completion by all patients diagnosed with COPD.
  • Complete it with your patients during a consultation or suggest they complete it themselves at home.

To access the CAT, go to

GOLD Guidelines 2

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) works with healthcare professionals and public health officials to raise awareness of COPD, and its guidelines aim to improve prevention and treatment. 2

  • GOLD guidelines provide a useful reference tool to help you ensure your management of COPD patients is in line with the latest advice and evidence.

Click to download a short summary of the GOLD Guidelines 2017

To access the GOLD guidelines, go to

The Modified Medical Research Council Dyspnoea Scale (mMRC)

The mMRC scale uses a simple grading system to assess your patient's level of dyspnoea or shortness of breath. This scale helps assess the degree of disability that breathlessness poses on the day-to-day activities of your patients. It measures a broad range of disability due to breathlessness, from only mild, up to severe limitations.

This diagram will support you when explaining the mMRC scale to your patients:

Adapted from The Medical Research Council Dyspnoea scale (mMRC dyspnea scale) 2


  1. Jones PW et al. Eur Respir J 2009; 34:648–654.
  2. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) 2017.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Anoro and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies